FOXO4-DRI vs Metformin
A side-by-side research comparison of FOXO4-DRI and Metformin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | FOXO4-DRI | Metformin |
|---|---|---|
| Full name | FOXO4-D-Retro-Inverso Peptide (Senolytic) | Metformin Hydrochloride |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved (off-label for longevity) |
| Mechanism | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. | Activates AMP-activated protein kinase (AMPK), inhibits mitochondrial complex I, reduces hepatic glucose output, and activates autophagy. Mimics the metabolic benefits of caloric restriction. |
| Molecular weight | ~4,500 Da | 165.62 Da |
| Half-life | 12-24 hours (D-amino acid stability) | ~6.2 hours |
| Bioavailability | Moderate (SubQ) | ~50-60% oral |
| Typical dose | 5-10 mg/kg (animal studies) | 500-1000 mg |
| Frequency | 3x per week for 3 weeks | 1-2x daily |
| Route | Subcutaneous | Oral tablet (extended-release preferred) |
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Metformin reported benefits
- AMPK activation
- Anti-aging cellular effects
- Cancer risk reduction
- Cardiovascular protection
- Blood sugar regulation
- Longevity support
Related comparisons
Research and educational reference only. Not medical advice.